School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants.
In a French randomized trial, children at school-age demonstrated no evidence of harm from fetal exposure to MgSO4 before very preterm birth. Motor dysfunction/death, qualitative behavioral disorders, cognitive difficulties, school grade repetition, and education services were decreased in the children exposed to MgSO4, although the differences were not significant.
Department of Neonatal Pediatrics and Intensive Care, Rouen University Hospital, Rouen, France; Region INSERM Team 28 "NeoVasc", Laboratory of Microvascular Endothelium and Neonate Brain Lesions, Institute for Biomedical Research, Rouen University, Rouen, France. Electronic address: clement.chollat@chu-rouen.fr.
Clément
C
Chollat
Department of Anesthetics and Intensive Care, Rouen University Hospital, Rouen, France.
Maya
M
Enser
Department of Biostatistics, Rouen University Hospital, Rouen, France.
Estelle
E
Houivet
Department of Anesthetics and Intensive Care, Rouen University Hospital, Rouen, France.
Delphine
D
Provost
Department of Biostatistics, Rouen University Hospital, Rouen, France.
Jacques
J
Bénichou
Region INSERM Team 28 "NeoVasc", Laboratory of Microvascular Endothelium and Neonate Brain Lesions, Institute for Biomedical Research, Rouen University, Rouen, France; Department of Obstetrics and Gynecology, Rouen University Hospital, Rouen, France.
Loïc
L
Marpeau
Department of Neonatal Pediatrics and Intensive Care, Rouen University Hospital, Rouen, France; Region INSERM Team 28 "NeoVasc", Laboratory of Microvascular Endothelium and Neonate Brain Lesions, Institute for Biomedical Research, Rouen University, Rouen, France.
Stéphane
S
Marret
D000293:Adolescent; D002547:Cerebral Palsy / Q000517:prevention & control*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D008278:Magnesium Sulfate